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Abstract
David D. Derse, Ph.D., Head of the Retrovirus Gene Expression Section in the HIV Drug
Resistance Program at the National Cancer Institute-Frederick (NCI-Frederick), passed away on
October 9, 2009, a scant six weeks after being diagnosed with liver cancer. It was with great
sadness that family, friends, and colleagues gathered together for his memorial service on Saturday,
October 17, 2009, at the Middletown United Methodist Church in Maryland. As a NCI scientist
since 1986, Dave studied the molecular mechanisms of infection and replication of a number of
different types of retroviruses. Dave became an internationally known expert on human T cell
lymphotrophic viruses type 1 and 2 (HTLV-1 and HTLV-2) and served on the editorial boards of
Virology and Retrovirology. His most recent studies focused on the mechanisms of HTLV-1 virion
morphogenesis, transmission, and replication.
Background
David Daniel Derse was born in Los Angeles, California,
on December 22, 1949. After graduating from California
State University Northridge with a B.S. in Chemistry in
1973, Dave worked as a research technician at Childrens
Hospital Los Angeles from 1974-1977 in the laboratory of
Dr. Richard L. Momparler, studying the biochemical phar-
macology of new anti-neoplastic agents. Dave earned his
Ph.D. in Pharmacology in 1982 from the State University
of New York (SUNY) at Buffalo. His graduate adviser at
SUNY Buffalo was Dr. Yung-Chi "Tommy" Cheng who
moved to the University of North Carolina at Chapel Hill
in 1979, and Dave completed his doctoral studies while
working with Tommy at UNC. While a graduate student
in 1981, Dave co-authored a paper with Dr. Gertrude B.
Elion who was later awarded The Nobel Prize in Physiol-
ogy or Medicine [1]. He trained with Dr. James Casey as a
post-doctoral fellow from 1982-1986, first at Louisiana
State University Health Sciences Center at New Orleans
and later at the National Cancer Institute in Frederick,
Maryland. While in the Casey laboratory, Dave identified
the enhancer elements in the long terminal repeat that
regulate bovine leukemia virus (BLV) gene expression,
publishing the data in Science [2]. Dave joined NCI-Fred-
erick as a Senior Staff Fellow in 1986, becoming a tenured
Senior Investigator in 1991. In 2004, Dave became Head
of the Retrovirus Gene Expression Section in the HIV Drug
Resistance Program at NCI-Frederick. Dave was also an
Adjunct Professor in the graduate program in Genetics at
George Washington University and served on the Execu-
tive Committee of the Center of Excellence in HIV/AIDS
and Cancer Virology, Center for Cancer Research at NCI-
Frederick.
During his tenure at NCI-Frederick, Dave identified and
characterized the molecular mechanisms of infection, rep-
lication, and pathogenesis of different retroviruses,
including equine infectious anemia virus (EIAV), bovine
leukemia virus (BLV), Moloney murine leukemia virus
(MLV), human immunodeficiency virus (HIV), and
human T lymphotrophic virus types 1 and 2 (HTLV-1,
HTLV-2). In recent years, the focus of Dave's research has
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into both the initial stages of infection and the assembly
and release of virions from infected cells (reviewed in [3]).
In studies directly comparing the infectivity of HTLV-1
and other retroviral cores, he reported that HTLV-1 is dra-
matically less efficient that other retroviruses, indicating a
post-entry block in replication. He identified motifs criti-
cal for the late stage of HTLV-1 assembly and character-
ized their relative roles in particle release. In 2007, he
published studies showing that a peptide motif in the C
terminus of the HTLV-1 nucleocapsid (NC) inhibits
APOBEC3G (hA3G) packaging into nascent virions,
thereby allowing HTLV-1 to evade an important aspect of
the body's antiviral defenses [4].
While Dave is known professionally for his scientific
accomplishments, he was perhaps best known by those
close to him as a devoted father, grandfather, and uncle.
Colleagues appreciated Dave's dry sense of humor, his
patience, and his love of teaching. In his personal life,
these qualities meant that children were especially drawn
to him. From birth to adulthood, the males in his
extended family knew Dave as a father figure. Their loss
reverberates across three generations. With his son, neph-
ews, and grandsons, he was always actively engaged,
whether it was throwing a ball, arm wrestling, fishing,
examining stones or seashells close up, planting a tree,
experimenting with dry ice, or stretching their imagina-
tions with heroic stories. To both his son James (Figure 1)
and his nephew Daniel, one challenged by learning disa-
bilities and the other by deafness, he gave the precious gift
of not lowering his expectations. He showed them again
and again that despite the obstacles they faced, he had
confidence that they would graduate from college and
succeed at whatever they chose to do in life. In return, they
loved him unconditionally. This is Dave's personal legacy.
Comments from Colleagues (in alphabetical 
order)
James Casey, Professor, Department of Microbiology and 
Immunology, Cornell University
Those of you who know artists understand that they see
things differently than us. They never introduce them-
selves as artists, it's apparent that they are. Dave was an
artist and actually received some artistic training early in
his life. A giveaway was Dave's method when drawing fig-
ures during lectures. The nervous circular motion of his
hand as he outlined a figure that had clarity, form and
completeness suddenly appeared on the board. This
unique artistic talent translated in his work as evidenced
by the tables and figures that he made for his papers. Pho-
toshop was not available during our time and likely
wouldn't have been used by Dave if it were. He ran endless
gels until the perfect one emerged that satisfied his artistic
sensibility and was scientifically reproducible. One inci-
dent, where a contentious plasmid construct wouldn't
grow despite numerous attempts and variations, did frus-
trate us but Dave's reply was, "it's not meant to be." Of
course he made successful constructs around the poison
sequence and got the answer needed. Dave's unassuming
and non-judgmental personality in accepting and kindly
dealing with others was punctuated by an impenetrable
ego when it came to his own personal science. In the end
Dave was given many gifts except for the gift of years..........
"It wasn't meant to be."
Genoveffa Franchini, Senior Investigator and Chief, Animal 
Models & Retroviral Vaccines Section, National Cancer 
Institute/NIH
David was one of the most generous scientist in terms of
the time and thoughts he would dedicate to your ques-
tions as well as his willingness to provide reagents that
may help to address them. His love for the training of
young investigators was reflected by his ability to always
find time for them. David was reserved, gentle and soft
spoken, but you knew you could call him and count on
him from help. David had a insatiable scientific curiosity,
rigorous and had an unusual ability to always assess the
biological importance of everyday experiments. He will be
missed by all of us in the field of retrovirology.
Chou-Zen Giam, Professor of Microbiology and 
Immunology, Uniformed Services University of the Health 
Sciences
I have known David since 1986 when his papers in Science
and the Journal of Virology on the comparative study of BLV
Tax and HTLV-1 Tax caught my attention. David's work
revealed fascinating similarities and differences in the
mechanism of action of these two proteins and served as
a guide for subsequent works in other labs showing the
exquisite specificity of interaction between Tax and the
Tax-responsive enhancer elements. Other highlights of
David's works include the generation of an infectious
molecular clone of HTLV-1 that made reversegenetics pos-
sible for HTLV-1; the study of the mechanism of cell-to-
cell transmission of HTLV-1; the in-depth analysis of ret-
roviral mRNA splicing and transport; and more recently,
the demonstration that the nucleocapsid of HTLV-1
antagonizes the packaging of APOBEC3G into viral parti-
cles, to name just a few.
My respect and fondness for David grew over the years
after a great deal of interactions in the annual Cold Spring
Harbor Retroviruses meetings and the international HTLV
meetings. On many occasions, he had alerted me to rele-
vant works from other laboratories and discussed them in
the broader context of earlier and present works in the
field. As a colleague, David was always generous in pro-
viding help and in sharing ideas and reagents. He was a
senior statesman in the HTLV/BLV field and served thePage 2 of 5
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emerging issues and chairing specific sessions. Although
David was somewhat of a "private" person, he had a great
sense of humor and was a lot of fun to be with when one
got to know him. David's untimely death is a great loss to
the field and his presence will be sorely missed in the years
to come.
Richard Gontarek, Associate Director, Cancer Research, 
GlaxoSmithKline Pharmaceuticals
I worked as a Post-doc with Dave from 1994-1996, and
although my tenure with him was somewhat brief, he had
a profound impact on my development as a scientist and
critical thinker. He thrived on discussing raw data hot off
the press, but he taught me to always be aware of the
larger context so that I could anticipate which experiments
to do next. He was someone who could see around scien-
tific corners and he inspired those of us who worked with
him to want to do the same. While Dave enjoyed his
responsibility to mentor young scientists, he put great
effort into learning things from us as well. In his lab he
cultivated a deep passion for science, but I will also fondly
remember it as a place where labmates could share laughs,
listen to classic rock music, and even dance if they wanted
to do so. As a scientist, mentor, and friend, Dave was just
a great person and will be missed.
Gisela Heidecker, Staff Scientist, Retrovirus Gene 
Regulation Section, Drug Resistance Program, National 
Cancer Institute-Frederick/NIH
Dave Derse was my friend and colleague for 25 years.
Most of this time we saw each other daily and worked
together closely; he actually was my boss for the last 10
years. He was the best friend, colleague and boss anybody
could ask for. He was kind, generous, funny (in a quiet
way) and very, very bright. He lived for science, and doing
it well was the most important thing to him. "Doing good
science" meant to him that you were more interested in
getting answers to scientific questions than to beat out the
other guy. He was very generous with his time and with
reagents he had generated to help the rest of the scientific
community. When he still did his own experiments, they
were always carefully designed and beautifully executed.
Later, when he was responsible for a whole lab, his direc-
tions were detailed, when needed, but he also left room
for his people to design their own experiments. Under his
directions many students and postdocs flourished in the
lab and went on to good positions in academia and indus-
try. At this point I still cannot imagine how the lab and I
will go on without him. However, we will all try to honor
his memory by doing our very best.
Stephen Hughes, Director, HIV Drug Resistance Program; 
Chief, Retroviral Replication Laboratory; and Head, 
Vector Design and Replication Section, National Cancer 
Institute-Frederick/NIH
I was privileged not only to have Dave Derse as a col-
league, but also as a friend and fishing buddy. Most of our
trips involved fly fishing for trout in western Maryland.
We fished the Casselman in the winter when both the air
temperature and the water temperature were 32°F, and a
mixture of sleet and rain fell from a leaden sky. We fished
Town Creek in the spring when there was the scent of new
life in the air and the first hints of green appeared on the
ends of the branches above the stream. We fished the
Gunpowder in the summer when walking down from the
parking lot to the stream in the canyon was like walking
from a city sidewalk into an air-conditioned building, and
the Savage in the fall when the stream ran gin clear and the
fish seemed to be magically suspended above the rocks
under a canopy of red and gold. The gift of those days was
not the fish we caught, but the chance to be out in some
of the most beautiful places on the east coast. I had the
best of it, because he was there. In all the years I knew him,
I never heard Dave say a negative word about another per-
son, or complain about anything, even when we were,
quite literally, wading in ice water. He was one of the
kindest and gentlest people I ever knew. His personality
David and James Derse at the wedding of James and Carrie erse on July 15, 2000, in Middl town, MarylandFigure 1
David and James Derse at the wedding of James and 
Carrie Derse on July 15, 2000, in Middletown, Mary-
land. Reprinted with permission from James Derse.Page 3 of 5
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influence on all who knew him. In the deepest and most
original sense, he was a good man.
Kuan-Teh Jeang, Senior Investigator and Chief, Molecular 
Virology Section, National Institute of Allergy and 
Infectious Diseases/NIH
When I heard about David's passing, I was devastated.
David's death followed closely on the heels of the passing
of three other notable HTLV-1 researchers, Ralph Grass-
mann [5], John Brady [6], and Bill Harrington [7]. David,
like the others, left us all too early. We will remember
David as a wonderfully accomplished virologist who
made many important contributions, too numerous to
list all of them. I do, however, want to mention one of
David's papers which has influenced and continues to
guide our research [8]. David's construction of an infec-
tious molecular clone for HTLV-1 was a remarkable break-
through; and even just a few days before David departed,
he was emailing my postdoctoral fellow giving us pointers
on how to use this HTLV-1 clone. Another point, our most
missed friends are ones who do great science and are also
outstanding citizens of our retrovirology community. I
shall remember David for his services to our community.
David was a member of our Retrovirology editorial board.
He and I also served together on the Norman Salzman
Memorial Symposium Committee. A couple of years ago,
when I was asked to head the NIH Virology Interest Group
(VIG), David was gracious in volunteering to be a member
of the VIG advisory board. "Hey, David, say hello to
Ralph, John and Bill for me. You guys have some fun up
there; don't forget us; we certainly won't forget you.".
Michael D. Lairmore, Professor and Chair, Department of 
Veterinary Biosciences; Associate Director for Basic 
Sciences, Comprehensive Cancer Center, The Ohio State 
University
David was an outstanding scientist and even a better per-
son. I felt I could trust his results and respected his opin-
ion. He was thorough scientist who asked fundamental
questions and tried to use the most current methods to
address. Above all else he was curious and his inquisitive
nature benefited all that knew him and allowed him to
contribute important findings to the retrovirology field.
We will miss him dearly.
Maureen Shuh, Associate Professor, Division of Basic 
Pharmaceutical Sciences, College of Pharmacy, Xavier 
University of Louisiana
I was one of the fortunate scientists who worked for Dave
as a post-doctoral fellow in his laboratory in 1996-2000.
From the time I joined his laboratory, we spent the next
13 years, right up to a few weeks before he became ill, giv-
ing each other grief about everything as well as discussing
science and politics. Dave was very passionate about sci-
ence, and his enthusiasm for work was contagious to
members of his laboratory. He taught me to be a thor-
ough, careful, thoughtful, and unselfish scientist, but
most important, he conveyed the same characteristics in
how he treated me as individual. Dave made several
important contributions to the field, and at the same time,
he never sought accolades for himself. He taught me not
only the science but also many aspects of life so that I
could be a better person. He watched out for me until the
very end of his life. Dave remains the most genuine and
kind individual I know. I cherish the years that I worked
with him, and I will always miss him.
Luc Willems, Cellular and Molecular Biology, Agro-Bio 
Tech (FUSAG), Gembloux, Belgium and Interdisciplinary 
Cluster for Applied Genoproteomics (GIGA), University of 
Liège (ULg), Belgium
I had the opportunity to meet Dave as a visiting post-doc
in 1990. What I first remember from him is his kindness.
He was really a very pleasant guy. He is also one of the best
scientists I met in my career. He was extremely cautious
and rigorous in his work. He performed essential break-
throughs in the BLV/HTLV field such as Tax-induced tran-
scriptional activation, Rex post-transcriptional regulation
and cell-free infection by HTLV-1.
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